The abstract is read at the publisher; the summary is JClub's.
Blocking the CCR1–CCR2 axis prevents inflammatory macrophage recruitment and substantially reduces cytokine release syndrome severity in preclinical CAR T-cell models.
- Why it matters: CRS is a major CAR T-cell side effect, but its underlying mechanisms are not fully defined and targeted treatments are limited.
- What they did: Li and colleagues identified the CCR1–CCR2 axis as a mediator of macrophage recruitment to CAR T-cell activation sites, then tested axis blockade in preclinical models.
- The result: CCR1/CCR2 inhibition prevented macrophage recruitment and substantially diminished CRS severity, suggesting a potential targeted strategy pending further clinically relevant validation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.